CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CURIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.38−0.03 (-6.26%)
Close on Oct 19, 2026
- Market cap
- $815.06K
- P/E (TTM)
- –
- Dividend yield
- –
Curis statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Curis | Industry median |
|---|---|---|
| Market Cap | $797.57K | $197.05M |
| Enterprise Value | -$4.30M | $106.56M |
| PS Ratio | 0.18 | 3.93 |
| PB Ratio | 0.17 | 2.14 |
Enterprise value
| Measure | Curis | Industry median |
|---|---|---|
| EV / Sales | -1.00 | 2.69 |
Income (trailing twelve months)
| Measure | Curis | Industry median |
|---|---|---|
| Revenue | $4.31M | $57.94M |
| Operating Income | -$8.76M | -$21.44M |
| Net Income | -$21.15M | -$22.46M |
| EBITDA | -$8.68M | -$16.91M |
Margins
| Measure | Curis | Industry median |
|---|---|---|
| Operating Margin | -203.2% | -44.5% |
| Profit Margin | -490.3% | -39.2% |
| EBITDA Margin | -201.2% | -31.3% |
Returns
| Measure | Curis | Industry median |
|---|---|---|
| Return on Assets (ROA) | -87.8% | -41.0% |
| Return on Capital Employed (ROCE) | -165.5% | -37.8% |
Growth
| Measure | Curis | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -62.2% | 6.01% |
| Revenue Growth (3Y CAGR) | -2.42% | 2.25% |
| Revenue Growth (5Y CAGR) | -2.71% | 6.42% |
Balance sheet
| Measure | Curis | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.10M | $62.42M |
| Net Cash (Debt) | $5.10M | $15.68M |
| Net Cash Per Share | $2.44 | $0.65 |
| Equity (Book Value) | $4.70M | $48.79M |
| Book Value Per Share | $2.25 | $1.36 |
| Tangible Book Value | -$4.29M | $23.06M |
| Working Capital | -$6.95M | $75.77M |
Financial position
| Measure | Curis | Industry median |
|---|---|---|
| Current Ratio | 0.49 | 3.30 |
| Quick Ratio | 0.37 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Curis | Industry median |
|---|---|---|
| Operating Cash Flow | -$30.59M | -$12.35M |
Efficiency
| Measure | Curis | Industry median |
|---|---|---|
| Asset Turnover | 0.18 | 0.38 |
| Revenue Per Employee | $179.75K | $398.96K |
| Profits Per Employee | -$881.38K | -$732.08K |
| Employee Count | 24 | 73 |
Dividends and yields
| Measure | Curis | Industry median |
|---|---|---|
| Earnings Yield | -2652.2% | -21.2% |
| Buyback Yield | -3083.0% | -0.58% |
| Shareholder Yield | -3083.0% | 0.00% |
Shares
| Measure | Curis | Industry median |
|---|---|---|
| Shares Outstanding | 2,090,080 | 59,128,900 |
| Shares Change (YoY) | 169.2% | 11.1% |
| Shares Change (QoQ) | -2.50% | 0.54% |
| Float | 1,664,700 | 48,744,500 |
| Shares Held by Insiders | 20.4% | 11.8% |
| Shares Held by Institutions | 0.00% | 59.4% |
Scores
| Measure | Curis | Industry median |
|---|---|---|
| Altman Z-Score | -96.18 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Curis's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.